Obstructive Sleep Apnea and Glycemic Variability in People With Diabetes: A Systematic Review and Meta-Analysis.

J Sleep ResMay 29, 2026 (epub)
Clinical ResearchEndocrinology

Jinjin Yuan, Yueying Wang, Pei Chen et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the relationship between obstructive sleep apnea (OSA) and glycemic variability (GV) in individuals with diabetes. The analysis included 14 studies, primarily focusing on type 2 diabetes. CPAP treatment was associated with a significant reduction in nocturnal standard deviation (SD) of glycemic levels (mean difference = -0.37, p = 0.001).

Key findings

  • CPAP treatment led to a significant reduction in nocturnal SD of glycemic levels (mean difference = -0.37, p = 0.001).
  • There was a marginally significant reduction in nocturnal mean amplitude of glycemic excursions (MAGE) (mean difference = -0.23, p = 0.050).
  • Significant reductions in mean of daily difference and mean of nocturnal glucose difference were observed after CPAP treatment.
  • Cross-sectional studies indicated possible associations between OSA severity and glycemic variability.

Why it matters

Understanding the impact of obstructive sleep apnea on glycemic variability is crucial for managing diabetes effectively. This association may influence treatment strategies and improve glycemic control in affected patients.

Source

PubMed · PMID 42213029

Published in J Sleep Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.